Chad E. Beyer

Chad Beyer is the President & CEO of Promentis Pharmaceuticals, Inc and is a Board of Directors member at Promentis. He is a pharmaceutical professional with nearly 20 years of experience in the research, discovery, and business development of medications aimed to treat CNS and neurological disorders. For more than a decade, Dr. Beyer worked in the Discovery Neuroscience group at Wyeth Pharmaceuticals in Princeton, NJ, holding positions of increasing responsibility including serving as the Head of Neurochemistry and leading the Psychiatry Task Force. During his career at Wyeth, Dr. Beyer led several early-stage drug discovery teams, managed a group responsible for contributing to the submission of more than 30 INDs, and provided supporting data for the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®. Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, co-edited “Next Generation Antidepressants” and is co-founder of the journal “Technology Transfer & Entrepreneurship.” Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches “Bioventure Management” and the business of doing science.